Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective
Journal of Medicinal Chemistry · 11.12.2025 · 68 (23) · 24830-24847
DOI: 10.1021/acs.jmedchem.5c02894 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 25.11.2025. Verfasst von David G Twigg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, U.K. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical, Drug Discovery. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 112 Literaturangaben.
Abstract (Originalsprache)
Fragment-based drug discovery (FBDD) has led to dozens of clinical compounds, including eight approved drugs. For the past decade, we have published an annual review of successful fragment-to-lead (F2L) medicinal chemistry programs. This Perspective marks the tenth in the series. We analyze the 18 F2L case studies from 2024 and put them in the context of the larger set of 233 examples dating back to 2015. We hope that the lessons herein will both inform and inspire researchers to discover the next generation of drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, U.K.
- Department of Pharmaceutical Chemistry and Small Molecule Discovery Center (SMDC), University of California San Francisco (UCSF), San Francisco, California 94158, United States.
- Frontier Medicines, 151 Oyster Point Blvd., South San Francisco, California 94080, United States.
- Division of Medicinal Chemistry, Amsterdam Institute of Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.
- Department of Biochemistry and Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, United States.
- Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232-0142, United States.
ORCID-Profile: David G Twigg, Michelle R Arkin, Daniel A Erlanson, Iwan J P de Esch, Barbara Farkaš, Stephen W Fesik, Wolfgang Jahnke, Christopher N Johnson
Zitieren
APA
Twigg, D. G., Arai, K., Arkin, M. R., Erlanson, D. A., de Esch, I. J. P., Farkaš, B., Fesik, S. W., Jahnke, W., Johnson, C. N., & Schroeder, M. (2025). Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective. Journal of Medicinal Chemistry, 68(23), 24830-24847. https://doi.org/10.1021/acs.jmedchem.5c02894
Vancouver
Twigg DG, Arai K, Arkin MR, Erlanson DA, de Esch IJP, Farkaš B, et al. Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective. Journal of Medicinal Chemistry. 2025;68(23):24830-24847. doi:10.1021/acs.jmedchem.5c02894
BibTeX
@article{Twigg2025,
author = {Twigg, David G and Arai, Kenta and Arkin, Michelle R and Erlanson, Daniel A and de Esch, Iwan J P and Farkaš, Barbara and Fesik, Stephen W and Jahnke, Wolfgang and Johnson, Christopher N and Schroeder, Martin},
title = {Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {23},
pages = {24830--24847},
doi = {10.1021/acs.jmedchem.5c02894}
}
EUVIMED